A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease
Phase of Trial: Phase I/II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs WVE 120102 (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRECISION-HD2
- 08 Aug 2017 According to a WaVe life Sciences media release, completion of this trial is anticipated for 2H 2019.
- 21 Jul 2017 New trial record
- 17 Jul 2017 Status changed from planning to recruiting.